Michelle Gilson
Stock Analyst at Morgan Stanley
(1.19)
# 3,442
Out of 4,711 analysts
30
Total ratings
33.33%
Success rate
-5.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Equal-Weight | $12 → $15 | $7.34 | +104.36% | 3 | Jun 6, 2024 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $51.40 | -41.63% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $4.39 | +287.24% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $136.38 | +43.72% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $17.18 | +161.93% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $11.68 | +550.68% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $65.66 | +38.59% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jun 6, 2024
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $7.34
Upside: +104.36%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $51.40
Upside: -41.63%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $4.39
Upside: +287.24%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $136.38
Upside: +43.72%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $17.18
Upside: +161.93%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $11.68
Upside: +550.68%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $65.66
Upside: +38.59%